公开(公告)号：US20240358827A1

公开(公告)日：2024-10-31

申请号：US18638633

申请日：2024-04-17

申请人： CELLTRION INC.

发明人： Joon Won LEE ,  Yeon Kyeong SHIN ,  Hye Young KANG ,  Kwang Woo KIM ,  So Young KIM ,  Su Jung KIM ,  Jun Seok OH ,  Won Yong HAN

IPC分类号： A61K39/395 ,  A61K9/08 ,  A61K47/12 ,  A61K47/18 ,  A61K47/26 ,  C07K14/525 ,  C07K16/00 ,  C07K16/24

CPC分类号： A61K39/39591 ,  A61K9/08 ,  A61K39/3955 ,  A61K47/12 ,  A61K47/183 ,  C07K16/00 ,  A61K47/26 ,  C07K14/525 ,  C07K16/241

摘要： Disclosed is a stable liquid formulation, comprising an antibody or antigen-binding portion thereof, an acetate buffer, glycine, and a surfactant, wherein the stable liquid formulation does not comprise at least one of sugar, a sugar alcohol and a metal salt, and the stable liquid formulation is still stable even upon high antibody content, and is superior in osmolality and viscosity, and subcutaneous administration thereof is possible.

公开(公告)号：US12129480B2

公开(公告)日：2024-10-29

申请号：US16956942

申请日：2018-12-21

申请人： GENENTECH, INC.

发明人： Chi Kin Domingos Ng ,  Yongping Guo Crawford ,  Amy Shen ,  Meixia Zhou ,  Bradley R. Snedecor ,  Shahram Misaghi ,  Albert Eric Gao

IPC分类号： C12N15/90 ,  C07K16/00

CPC分类号： C12N15/907 ,  C07K16/00 ,  C12N15/90 ,  C07K2317/51 ,  C07K2317/515 ,  C12N2800/30 ,  C12N2800/90 ,  C12N2840/00

摘要： The presently disclosed subject matter relates to targeted integration (TI) host cells suitable for the expression of recombinant proteins, as well as methods of producing and using said TI host cells.

公开(公告)号：US12129300B2

公开(公告)日：2024-10-29

申请号：US18501419

申请日：2023-11-03

申请人： Dragonfly Therapeutics, Inc.

发明人： Gregory P. Chang ,  Ann F. Cheung ,  Asya Grinberg ,  William Haney ,  Bradley M. Lunde ,  Bianka Prinz

IPC分类号： C07K16/00 ,  A61K39/395 ,  C07K16/28 ,  C07K16/32 ,  C12P21/08 ,  C07K1/00

CPC分类号： C07K16/2851 ,  C07K16/2803 ,  C07K16/283 ,  C07K16/32 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2317/94

摘要： Antibody heavy chain variable domains that can be paired with antibody light chain variable domains to form an antigen-binding site targeting the NKG2D receptor on natural killer cells are described. Proteins comprising an NKG2D antigen-binding site, pharmaceutical compositions and therapeutic methods thereof, including for the treatment of cancer, are also described.

公开(公告)号：US20240350662A1

公开(公告)日：2024-10-24

申请号：US18512804

申请日：2023-11-17

申请人： DNARx

发明人： Robert James DEBS ,  Timothy D. HEATH ,  Chakkrapong HANDUMRONGKUL

IPC分类号： A61K48/00 ,  A61K9/127 ,  A61K31/19 ,  A61K31/522 ,  A61K31/573 ,  A61K38/19 ,  A61K38/48 ,  A61K39/395 ,  A61K47/69 ,  C07K16/00 ,  C07K16/28 ,  A61K31/00 ,  A61K39/00 ,  C07H21/04 ,  C12N15/85

CPC分类号： A61K48/0016 ,  A61K9/1272 ,  A61K31/19 ,  A61K31/522 ,  A61K31/573 ,  A61K38/193 ,  A61K38/4846 ,  A61K39/395 ,  A61K47/6911 ,  A61K48/0066 ,  A61K48/0083 ,  C07K16/00 ,  C07K16/2887 ,  C12Y304/21022 ,  A61K31/00 ,  A61K2039/505 ,  A61K2039/53 ,  A61K48/005 ,  C07H21/04 ,  C07K2317/24 ,  C12N15/85

摘要： The present invention provides compositions, systems, kits, and methods for generating expression of one or more proteins and/or biologically active nucleic acid molecules in a subject (e.g., at therapeutic levels for extended periods required to produce therapeutic effects). In certain embodiments, systems and kits are provided that comprise a first composition comprising a first amount of polycationic structures, and a second composition comprising a therapeutically effective amount of expression vectors (e.g., non-viral expression vectors not associated with liposomes) that are CpG-free or CpG-reduced, where the expression vectors comprise a first nucleic acid sequence encoding: i) a first therapeutic protein or proteins, and/or ii) a first biologically active nucleic acid molecule or molecules.

公开(公告)号：US12122845B2

公开(公告)日：2024-10-22

申请号：US17397559

申请日：2021-08-09

申请人： EUTILEX CO., LTD.

发明人： Byoung S. Kwon ,  Hanna Lee ,  Yeonji Oh ,  Jin Sung Park

IPC分类号： C07K16/00 ,  A61P35/00 ,  C07K16/28 ,  C07K16/32 ,  A61K39/00

CPC分类号： C07K16/32 ,  A61P35/00 ,  C07K16/2878 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/522 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/92

摘要： A bispecific epitope binding protein having a multimer of four single-chain chimeric polypeptides of two single-chain chimeric heavy chains and two single-chain chimeric light chains. The bispecific epitope binding protein has a first antigen binding domain that binds specifically to HER2 and a second antigen binding domain that binds specifically to 4-1BB.

公开(公告)号：US12122840B2

公开(公告)日：2024-10-22

申请号：US18425859

申请日：2024-01-29

申请人： Chugai Seiyaku Kabushiki Kaisha

发明人： Tomoyuki Igawa ,  Hiroyuki Tsunoda ,  Tatsuhiko Tachibana ,  Taichi Kuramochi

IPC分类号： C07K16/28 ,  A61K39/395 ,  C07K16/00 ,  G01N33/68

CPC分类号： C07K16/2866 ,  A61K39/39591 ,  C07K16/00 ,  C07K16/28 ,  G01N33/6854 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/732

摘要： The present inventors provide methods for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the charge of at least one exposable amino acid residue on the surface of the complementarity determining region (CDR). The present invention also provides methods for purifying multispecific antibodies, comprising modifying isoelectric point, and methods for improving the plasma pharmacokinetics of antibodies, comprising modifying isoelectric point. The present invention further provides antibodies with a modified isoelectric point, pharmaceutical compositions comprising the antibodies as an active ingredient, and methods for producing the antibodies and compositions.

公开(公告)号：US20240343778A1

公开(公告)日：2024-10-17

申请号：US18540092

申请日：2023-12-14

申请人： ALX Oncology Inc.

发明人： Jaume PONS ,  Laura DEMING ,  Corey GOODMAN ,  Bang Janet SIM ,  Steven Elliot KAUDER ,  Hong WAN ,  Tracy Chia-Chien KUO

IPC分类号： C07K14/705 ,  A61K38/00 ,  A61K38/17 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61K47/68 ,  C07K14/47 ,  C07K16/00 ,  C07K16/28

CPC分类号： C07K14/70596 ,  A61K38/177 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6811 ,  C07K14/70503 ,  C07K16/00 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/2863 ,  A61K38/00 ,  A61K38/1709 ,  A61K2039/505 ,  C07K14/4703 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/30

摘要： The present disclosure features signal-regulatory protein α (SIRP-α) polypeptides and constructs that are useful, e.g., to target a cell (e.g., a cancer cell or a cell of the immune system), to increase phagocytosis of the target cell, to eliminate immune cells such as regulatory T-cells, to kill cancer cells, to treat a disease (e.g., cancer) in a subject, or any combinations thereof. The SIRP-α constructs include a high affinity SIRP-α D1 domain or variant thereof that binds CD47 with higher affinity than a wild-type SIRP-α. The SIRP-α polypeptides or constructs include a SIRP-α D1 variant fused to an Fc domain monomer, a human serum albumin (HSA), an albumin-binding peptide, or a polyethylene glycol (PEG) polymer. Compositions provided herein include (i) a polypeptide including a signal-regulatory protein α (SIRP-α) D1 variant and (ii) an antibody.

公开(公告)号：US12116419B2

公开(公告)日：2024-10-15

申请号：US18157752

申请日：2023-01-20

申请人： SYSMEX CORPORATION

发明人： Shingo Maeta ,  Atsushi Fukunaga ,  Reema Bajaj

IPC分类号： C07K16/00 ,  C07K16/26 ,  C07K16/32 ,  C07K16/40 ,  G16B15/20 ,  G16B20/30

CPC分类号： C07K16/40 ,  C07K16/00 ,  C07K16/26 ,  C07K16/32 ,  G16B15/20 ,  G16B20/30 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/92

摘要： Disclosed is a method for improving affinity of an antibody for an antigen, comprising, in an unmodified antibody, improving affinity for an antigen as compared to the unmodified antibody, by changing 18th, 20th and 22nd amino acid residues of a light chain defined by Kabat method to charged amino acid residues.

公开(公告)号：US12110312B2

公开(公告)日：2024-10-08

申请号：US16908401

申请日：2020-06-22

申请人： Genzyme Corporation

发明人： Konstantin Konstantinov ,  Rahul Godawat ,  Veena Warikoo ,  Sujit Jain

IPC分类号： B01D15/18 ,  B01D15/32 ,  B01D15/34 ,  B01D15/36 ,  B01D15/38 ,  B01D15/42 ,  C07K1/16 ,  C07K1/18 ,  C07K1/22 ,  C07K1/36 ,  C07K16/00 ,  C12M1/00 ,  C12N9/00 ,  C12N9/24 ,  C12N9/40 ,  C12P21/00

CPC分类号： C07K1/22 ,  B01D15/1807 ,  B01D15/1864 ,  B01D15/1871 ,  B01D15/327 ,  B01D15/34 ,  B01D15/362 ,  B01D15/363 ,  B01D15/3809 ,  B01D15/3814 ,  B01D15/422 ,  C07K1/16 ,  C07K1/18 ,  C07K1/36 ,  C07K16/00 ,  C12M23/52 ,  C12M47/10 ,  C12M47/12 ,  C12N9/00 ,  C12N9/2402 ,  C12N9/2465 ,  C12P21/00 ,  C12P21/005 ,  C12Y302/01022 ,  C12Y302/01045 ,  C07K2317/14

摘要： Provided herein are integrated continuous biomanufacturing processes for producing a therapeutic protein drug substance. Also provided are systems that are capable of continuously producing a therapeutic protein drug substance.

公开(公告)号：US12103966B2

公开(公告)日：2024-10-01

申请号：US17837888

申请日：2022-06-10

申请人： Rutgers, The State University of New Jersey

发明人： Renata Pasqualini ,  Wadih Arap ,  Fernanda Iamassaki Staquicini ,  Fortunato Ferrara ,  Sara D'Angelo ,  Andrew R. M. Bradbury

IPC分类号： C07K16/18 ,  A61K39/395 ,  A61K47/68 ,  A61P35/00 ,  C07K16/30 ,  G01N33/574 ,  A61K38/07 ,  A61K39/00 ,  A61K49/00 ,  C07K14/47 ,  C07K16/00 ,  C07K16/28 ,  C12N15/10 ,  C12N15/64 ,  C12Q1/6869 ,  G01N33/50

CPC分类号： C07K16/18 ,  A61K39/3955 ,  A61K39/39558 ,  A61K47/6803 ,  A61K47/68031 ,  A61K47/68033 ,  A61P35/00 ,  C07K16/30 ,  C07K16/3023 ,  G01N33/574 ,  A61K38/07 ,  A61K2039/505 ,  A61K47/6817 ,  A61K47/6843 ,  A61K47/6849 ,  A61K47/6891 ,  A61K49/0008 ,  C07K14/47 ,  C07K16/005 ,  C07K16/28 ,  C07K16/2866 ,  C07K2317/21 ,  C07K2317/35 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/77 ,  C12N15/1037 ,  C12N15/64 ,  C12N2810/00 ,  C12Q1/6869 ,  G01N33/5011 ,  G01N33/57423

摘要： Isolated or recombinant EphA5 or GRP78 targeting antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. A method of rapidly identifying antibodies or antibody fragments for the treatment of cancer using a combination of in vitro and in vivo methodologies is also provided.